Merck & Co.'s Keytruda Posts $8B in Q1 2026 as Qlex Picks Up Steam on May 01, 2026 Antineoplastic Agents earnings Keytruda Merck patent cliff pharmaceutical sales Qlex Subcutaneous Injections +
Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach on September 22, 2025 Approved Biosimilars checkpoint inhibitors Immunotherapy for cancer Keytruda Keytruda Qlex Merck patent expiration Solid Neoplasm Subcutaneous Injections United States Food and Drug Administration +
Eisai Secures FDA Approval for Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s Patients on September 02, 2025 Alzheimer 's disease Approved at-home AutoInjector Biogen dosing Eisai Lecanemab Leqembi Maintenance Subcutaneous Injections United States Food and Drug Administration +
FDA Approves CSL's Andembry, Directly Competing With Takeda's Takhzyro in HAE on June 17, 2025 Andembry Angioedemas, Hereditary Approved dosing factor XIIa garadacimab-gxii Inhibitor SMPX gene Subcutaneous Injections Takeda Takhzyro United States Food and Drug Administration +